Market Access | Getting therapies in patients' hands

News

US puts $125m into personalised RNA therapy production

Federal funding from ARPA-H of $125m, awarded to five groups, is part of a drive to accelerate patient access to personalised genetic medicines.

News

Enhertu OK ends 10-year EU gap in frontline breast cancer

Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.

News

White House signs pricing deals with nine more pharmas

Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.

News

FDA clears Takeda, Protagonist's first-in-class PV drug

Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.

Market Access

Navigating Europe's AI regulatory labyrinth: A strategic gui...

For US drug developers, bringing AI tools across the Atlantic introduces steep regulatory hurdles.

Views & Analysis

Secret US-UK talks on drug pricing revealed

Despite the UK still not leaving the European Union – pencilled in for the 31 January 2020 at the time of writing – the need to strike new trade deals has led to secret trade discussions be

News

Corbyn accuses Tories of planning deal to hike drug prices w...

Drug prices have become an issue in the UK’s general election, after Labour leader Jeremy Corbyn accused the Conservatives of planning a shady deal with Donald Trump that would see the NHS

News

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

News

US puts $125m into personalised RNA therapy production

Federal funding from ARPA-H of $125m, awarded to five groups, is part of a drive to accelerate patient access to personalised genetic medicines.

News

Enhertu OK ends 10-year EU gap in frontline breast cancer

Enhertu plus Perjeta has become the first new frontline therapy approved for advanced HER2-positive breast cancer in the EU for over a decade.

Press Releases

Partner Content

Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...

EVERSANA will provide comprehensive end-to-end commercialization services for Xcovery

Market Access

VuuAI and Amiculum partner to transform content engagement i...

Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat

Views & Analysis

Market Access

Navigating Europe's AI regulatory labyrinth: A strategic gui...

For US drug developers, bringing AI tools across the Atlantic introduces steep regulatory hurdles.

Market Access

Biotech funding has returned. The bar has moved with it.

For biotech sponsors, the question worth asking is not whether the rebound is real, but what it is actually rewarding.

Deep Dive

Market Access

Can direct-to-employer models close the GLP-1 obesity care g...

Market Access

The expanding role of early-phase trials in modern drug deve...

Market Access

Market Access 2026

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

IQVIA Webinar on Innovative Medicines Fund

Sponsored

Innovative Medicines Fund and the opportunity for ICSs to mo...

In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help improve patient access to cutting-edge medicines, with a particular focus on rare diseases, and en

Webinars

Sponsored

Medical Informatics and Rare Disease: a bridge between two w...

With more than 6,000 different diseases comprising the rare disease (RD) landscape, connecting patients and practitioners with the expertise needed to achieve th

Webinars

Sponsored

ICSs - an opportunity to improve Patient & Market Access at ...

With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in the UK are preparing to navigate the most significant piece of NHS legislation in

Podcasts

Market Access

pharmaphorum podcast Episode 270, Alice Valder Curran, Hogan Lovells

Policy in Focus: What’s new with CMS drug price negotiation,...

Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.

Market Access

Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...

Unpack the impact of Most-Favoured Nations in GLOBE and GUARD pricing models, and TrumpRx, with Alice Valder Curran's clear policy overview.

Market Access

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Policy experts Alice Valder Curran and Elizabeth Jungman of Hogan Lovells weigh in on Trump's MFN deals, FDA vouchers, and the government shutdown.

Video

Patients

Interview with Matt Wadyka at Reuters Pharma USA 2026

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

Market Access

Interview with Marjorie Sidhoum at BIO Europe 2026

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Marjorie Sidhoum, vice president of business development & corporate communication at Kainova Therapeutics, discusses their immuno-oncology pipeline.

Market Access

Consolidating data strategy for global success: Insights fro...

At Frontiers Health 2025, Drew McCormick, Head of Data and Analytics at EVERSANA, emphasised a critical truth: data strategy is launch strategy.

White Papers

Spotlight on

Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Market Access

Sponsored

Navigating Routes to Commercial Excellence in Cell and Gene ...

'Navigating Routes to Commercial Success in Cell and Gene Therapy', authored by Franjo Hanzl, VP, Business Development, Commercial at EVERSANA, Dr.

Debates & Insight

Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Media Partner

30th Portfolio Decision-Making & Prioritisation for Pharma

Pharmaceutical portfolio decision-making is facing structural pressure.

Event

Partner Content

The MFN effect: what payers expect and how Pharma should res...

A live webinar and audience Q&A with practical insights from global payer research and leading payer experts

Event

Partner Content

The Pharmaceutical Launch Excellence Summit

Where pharma leaders share strategies for successful drug launches.

Market Access

Sponsored

Innovative contracting in Europe – a Trojan horse?

Overview

Market Access

Sponsored

Launch excellence in a disrupted world – challenges & opport...

Overview

Market Access

Sponsored

Orphan medicines launch excellence: sustaining launch succes...

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

Partner Content

Event

Media Partner

30th Portfolio Decision-Making & Prioritisation for Pharma

Pharmaceutical portfolio decision-making is facing structural pressure.

Event

Partner Content

The MFN effect: what payers expect and how Pharma should res...

A live webinar and audience Q&A with practical insights from global payer research and leading payer experts

Event

Partner Content

The Pharmaceutical Launch Excellence Summit

Where pharma leaders share strategies for successful drug launches.

US puts $125m into personalised RNA therapy production

Enhertu OK ends 10-year EU gap in frontline breast cancer

White House signs pricing deals with nine more pharmas

FDA clears Takeda, Protagonist's first-in-class PV drug

Navigating Europe's AI regulatory labyrinth: A strategic gui...

Secret US-UK talks on drug pricing revealed

Corbyn accuses Tories of planning deal to hike drug prices w...

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

US puts $125m into personalised RNA therapy production

Enhertu OK ends 10-year EU gap in frontline breast cancer

Xcovery Partners with EVERSANA to Commercialize Lung Cancer ...

VuuAI and Amiculum partner to transform content engagement i...

Navigating Europe's AI regulatory labyrinth: A strategic gui...

Biotech funding has returned. The bar has moved with it.

Can direct-to-employer models close the GLP-1 obesity care g...

The expanding role of early-phase trials in modern drug deve...

Market Access 2026

Innovative Medicines Fund and the opportunity for ICSs to mo...

Medical Informatics and Rare Disease: a bridge between two w...

ICSs - an opportunity to improve Patient & Market Access at ...

Policy in Focus: What’s new with CMS drug price negotiation,...

Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al...

Policy in Focus: Trump’s MFN deals, FDA vouchers, and the go...

Making direct-to-patient work, with Matt Wadyka

BIO-Europe Spring 2026: In conversation with Marjorie Sidhou...

Consolidating data strategy for global success: Insights fro...

Life Sciences Industry Report 2025

Navigating Routes to Commercial Excellence in Cell and Gene ...

Pricing & Market Access Outlook 2015/2016 Edition

30th Portfolio Decision-Making & Prioritisation for Pharma

The MFN effect: what payers expect and how Pharma should res...

The Pharmaceutical Launch Excellence Summit

Innovative contracting in Europe – a Trojan horse?

Launch excellence in a disrupted world – challenges & opport...

Orphan medicines launch excellence: sustaining launch succes...

30th Portfolio Decision-Making & Prioritisation for Pharma

The MFN effect: what payers expect and how Pharma should res...

The Pharmaceutical Launch Excellence Summit

PMV cues up filing for first p53-directed cancer therapy

Discover a new era of healthcare panel engagement: Grounded ...

News

Press Releases

Views & Analysis

Editor's Picks

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Debates & Insight

Partner Content

Editor's Picks